Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cardiff Oncology, Inc.CRDF · Entity 6917 | Director | July 14, 2026 | July 16, 2026 |
| Pacira BioSciences, Inc.PCRX · Entity 4928 | Director | March 06, 2024 | March 08, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cardiff Oncology, Inc.
Report date July 14, 2026 · Filed July 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,043,661 |
Reported balance
After 2026-07-14 transaction · row 1
1 source rowRow 1 · 2026-07-14 · Purchase · Acquired 687,285 · Balance 2,043,661 |
| Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $1.33 | Direct | 687,285 |
Reported balance
After 2026-07-14 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-14 · Purchase · Acquired 687,285 · Balance 687,285 F1: Exercisable beginning on the later of (i) six months after issuance or (ii) the Authorized Share Increase Date (the "Initial Exercise Date"). "Authorized Share Increase Date" means the date on which an amendment to the Issuer's certificate of incorporation increasing the number of authorized shares of its common stock to an amount sufficient for the exercise in full of the Common Warrants is filed with and accepted by the State of Delaware, subject to approval of such amendment by its stockholders. F2: The term of exercise is equal to five and one-half years after the Initial Exercise Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Exercisable beginning on the later of (i) six months after issuance or (ii) the Authorized Share Increase Date (the "Initial Exercise Date"). "Authorized Share Increase Date" means the date on which an amendment to the Issuer's certificate of incorporation increasing the number of authorized shares of its common stock to an amount sufficient for the exercise in full of the Common Warrants is filed with and accepted by the State of Delaware, subject to approval of such amendment by its stockholders.
F2: The term of exercise is equal to five and one-half years after the Initial Exercise Date.
Pacira BioSciences, Inc.
Report date March 06, 2024 · Filed March 08, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,127 |
Ending reported balance
After 2024-03-08 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2024-03-06 · Sale · Disposed 1,066 · Balance 140,384 Row 2 · 2024-03-07 · Sale · Disposed 28,257 · Balance 112,127 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.550 to $30.965, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 1 and 2. Row 3 · 2024-03-08 · Sale · Disposed 90,000 · Balance 22,127 F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.300 to $30.860, inclusive. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.550 to $30.965, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes 1 and 2.
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $30.300 to $30.860, inclusive.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
RESMED INC
Report date July 24, 2019 · Filed July 24, 2019
Section 16 reporting ended · disclosed 2019-07-24. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 16, 2020 Filed Sep 17, 2020 13:42 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 850 | $5.71 | $4,853.50 |
DisclosureSEC source: 0001628280-20-013688 · wf-form4_160035013609004.xml · nonDerivative · entry 2 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,311 Read SEC document |
| September 16, 2020 Filed Sep 17, 2020 13:42 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 1,700 | $5.69 | $9,673.00 |
DisclosureSEC source: 0001628280-20-013688 · wf-form4_160035013609004.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,461 Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 20:17 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | GrantStock Options · Derivative | 28,858 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001104659-20-075244 · a4.xml · derivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,774 Underlying: Common Stock · 28,858 shares Expires 2030-06-17 Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 22:27 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 8,027 | $0.00 Strike: $47.65 | $0.00 |
DisclosureSEC source: 0001209191-20-036044 · doc4.xml · derivative · entry 2 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,027 Underlying: Common Stock · 8,027 shares Expires 2030-06-09 Read SEC document |
| June 09, 2020 Filed Jun 11, 2020 22:27 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 1,260 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-036044 · doc4.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,949 F1 · shares: Represents restricted stock units that vest on June 3, 2021, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| May 11, 2020 Filed May 13, 2020 20:16 UTC | Cardiff Oncology, Inc. CRDF · Entity 6917 | PurchaseCommon Stock | 447,761 | $1.34 | $599,999.74 |
DisclosureSEC source: 0001104659-20-060862 · a4.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 447,761 Read SEC document |
| April 16, 2020 Filed May 1, 2020 20:17 UTC | Cardiff Oncology, Inc. TROV · Entity 6917 | GrantStock Options · Derivative | 11,916 | $0.00 Strike: $0.98 | $0.00 |
DisclosureSEC source: 0001104659-20-055492 · a4.xml · derivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,916 Underlying: Common Stock · 11,916 shares Expires 2030-04-16 F1 · derivative.exercise_date: 3,972 of the Stock Options vest on each of 4/16/2021, 2022 and 2023 Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 21:54 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $13.98 | $0.00 |
DisclosureSEC source: 0001209191-20-019350 · doc4.xml · derivative · entry 8 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2021-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The option vested in 12 equal monthly installments beginning on July 2, 2011. Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 21:54 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,438 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001209191-20-019350 · doc4.xml · derivative · entry 7 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,438 shares Expires 2020-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option vested as to 50% of the option shares on September 2, 2010 and, as to the remaining 50% of the option shares, in successive equal monthly installments for the subsequent 24 months. The option shares became exercisable, to the extent vested, from and after the issuer's initial public offering. Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 21:54 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,649 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001209191-20-019350 · doc4.xml · derivative · entry 6 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,649 shares Expires 2020-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vested as to 50% of the option shares upon the first anniversary of the issuer's initial public offering and, as to the remaining 50% of the option shares, upon the second anniversary of the issuer's initial public offering. The option shares became exercisable, to the extent vested, from and after the issuer's initial public offering. Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 21:54 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,649 | $0.00 Strike: $1.61 | $0.00 |
DisclosureSEC source: 0001209191-20-019350 · doc4.xml · derivative · entry 5 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,649 shares Expires 2020-09-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The option vested as to 25% of the option shares on September 2, 2011 and, as to the remaining shares, in successive equal monthly installments for the subsequent 36 months. The option shares became exercisable, to the extent vested, from and after the issuer's initial public offering. Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 21:54 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 5,000 | $13.98 | $69,900.00 |
DisclosureSEC source: 0001209191-20-019350 · doc4.xml · nonDerivative · entry 4 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 21:54 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 7,438 | $1.61 | $11,975.18 |
DisclosureSEC source: 0001209191-20-019350 · doc4.xml · nonDerivative · entry 3 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 21:54 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 4,649 | $1.61 | $7,484.89 |
DisclosureSEC source: 0001209191-20-019350 · doc4.xml · nonDerivative · entry 2 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,251 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 12, 2020 Filed Mar 16, 2020 21:54 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | Exercise / conversionCommon Stock | 4,649 | $1.61 | $7,484.89 |
DisclosureSEC source: 0001209191-20-019350 · doc4.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,602 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 20:52 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 8,437 | $0.00 Strike: $43.54 | $0.00 |
DisclosureSEC source: 0001209191-19-035120 · doc4.xml · derivative · entry 2 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,437 Underlying: Common Stock · 8,437 shares Expires 2029-06-05 F2 · derivative.exercise_date: The stock option vests and becomes exercisable on the first anniversary of the grant date, provided that the reporting person remains in continuous service with the issuer through the vesting date. Read SEC document |
| June 05, 2019 Filed Jun 6, 2019 20:52 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 4,134 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-035120 · doc4.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,953 F1 · shares: Represents restricted stock units that vest on June 3, 2020, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| November 19, 2018 Filed Nov 21, 2018 21:07 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | PurchaseCommon Stock | 4,500 | $46.18 | $207,810.00 |
DisclosureSEC source: 0001209191-18-059710 · doc4.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,819 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $45.92 to $46.31, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| November 07, 2018 Filed Nov 9, 2018 21:30 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | PurchaseCommon Stock | 4,000 | $51.29 | $205,160.00 |
DisclosureSEC source: 0001209191-18-057963 · doc4.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,319 F1 · price: The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $50.98 to $51.69, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 23:17 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 4,693 | $0.00 Strike: $38.35 | $0.00 |
DisclosureSEC source: 0001209191-18-038197 · doc4.xml · derivative · entry 2 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,693 Underlying: Common Stock · 4,693 shares Expires 2028-06-13 F2 · derivative.exercise_date: The stock option vests and becomes exercisable on the first anniversary of the grant date, provided that the reporting person remains in continuous service with the issuer through the vesting date. Read SEC document |
| June 13, 2018 Filed Jun 15, 2018 23:17 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 782 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-038197 · doc4.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,319 F1 · shares: Represents restricted stock units that vest on June 3, 2019, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| May 08, 2018 Filed May 10, 2018 11:07 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Stock Options · Derivative | 28,403 | $0.00 Strike: $27.58 | $0.00 |
DisclosureSEC source: 0001140361-18-022661 · doc1.xml · derivative · entry 3 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 28,403 shares Expires 2018-11-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Represents date options first became exercisable. Read SEC document |
| May 08, 2018 Filed May 10, 2018 11:07 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 28,403 | $97.37 | $2,765,600.11 |
DisclosureSEC source: 0001140361-18-022661 · doc1.xml · nonDerivative · entry 2 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,578 F1 · price: This transaction was executed in multiple trades at prices ranging from $96.99 to $97.87. The price reported above reflects the weighted average sale price. Read SEC document |
| May 08, 2018 Filed May 10, 2018 11:07 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 28,403 | $27.58 | $783,354.74 |
DisclosureSEC source: 0001140361-18-022661 · doc1.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,981 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 16, 2017 Filed Nov 18, 2017 02:46 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 2,991 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-043281 · doc1.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,578 F1 · shares: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2018, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 15:20 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 22,660 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-17-025248 · doc1.xml · derivative · entry 6 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 22,660 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest one full year following the grant date. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 15:20 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 22,660 | $76.00 | $1,722,160.00 |
DisclosureSEC source: 0001140361-17-025248 · doc1.xml · nonDerivative · entry 4 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,587 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 15:20 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 22,660 | $33.70 | $763,642.00 |
DisclosureSEC source: 0001140361-17-025248 · doc1.xml · nonDerivative · entry 3 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,247 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 15:20 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 1,730 | $0.00 Strike: $33.70 | $0.00 |
DisclosureSEC source: 0001140361-17-025248 · doc1.xml · derivative · entry 5 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,660 Underlying: ResMed Common Stock · 1,730 shares Expires 2017-11-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest one full year following the grant date. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 15:20 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 1,730 | $76.00 | $131,480.00 |
DisclosureSEC source: 0001140361-17-025248 · doc1.xml · nonDerivative · entry 2 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,587 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 14, 2017 Filed Jun 16, 2017 15:20 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 1,730 | $33.70 | $58,301.00 |
DisclosureSEC source: 0001140361-17-025248 · doc1.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,317 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| June 14, 2017 Filed Jun 17, 2017 00:17 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantStock Option (Right to Buy) · Derivative | 2,714 | $0.00 Strike: $44.20 | $0.00 |
DisclosureSEC source: 0001209191-17-040693 · doc4.xml · derivative · entry 2 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,714 Underlying: Common Stock · 2,714 shares Expires 2027-06-14 F2 · derivative.exercise_date: The stock option vests and becomes exercisable on the first anniversary of the grant date, provided that the reporting person remains in continuous service with the issuer through the vesting date. Read SEC document |
| June 14, 2017 Filed Jun 17, 2017 00:17 UTC | Pacira BioSciences, Inc. PCRX · Entity 4928 | GrantCommon Stock | 1,357 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-040693 · doc4.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,537 F1 · shares: Represents restricted stock units that vest on June 3, 2018, provided that the reporting person remains in continuous service with the issuer through the vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 01:58 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 4,429 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-16-087150 · doc1.xml · nonDerivative · entry 1 PACE GARY W · CIK 0001184778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,587 F1 · shares: Shares awarded represent Restricted Stock Units. The RSUs cliff vest on the earlier of 11/11/2017, or the annual shareholder's meeting in the year following the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.